Novavax is seeking emergency authorization of its COVID-19 booster shot in adults aged 18 and older from U.S. regulators, the company announced on Monday.
In a press release, the biotechnology company based in Maryland said it has submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for its protein-based booster shot.
If authorized, the Novavax vaccine would be the first protein-based COVID-19 booster for adults.
“It’s important for people to have a choice as they evaluate how to stay protected against COVID-19, and boosters are an invaluable tool to build upon immunity obtained from previous vaccinations,” said Novavax President and CEO Stanley Erck in a statement….